Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) Stock Price & Analysis

0 Followers

8329 Stock Chart & Stats

HK$0.14-HK$0.00(-0.72%)
At close: 4:00 PM GMT+8
HK$0.1HK$0.12HK$0.14Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 0.13 - HKD 0.14
52-Week Range
HKD 0.09 - HKD 0.18
Previous Close
HKD 0.14
Volume
N/A
Average Volume (3M)
826.33K
Market Cap
HKD 233.24M
Enterprise Value
HKD 111.20M
Total Cash (Recent Filing)
HKD 212.22M
Total Debt (Recent Filing)
HKD 96.37M
Price to Earnings (P/E)
―
Beta
0.11
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
Dec 10, 2026
Dividend Yield
3.86%

Bulls Say, Bears Say

Bulls Say

Revenue Rebound

The 19.3% TTM revenue rebound indicates renewed top-line momentum after softer prior growth. If sustained, stronger sales can improve operating leverage, support reinvestment in the specialty and generic pharmaceutical business, and reinforce the company’s market position over coming quarters.

Cash Generation

Positive operating cash flow and sizable free cash flow provide internally generated funding for ongoing operations and investment despite reported losses. This supports liquidity and reduces reliance on external financing, although maintaining this cash conversion remains important for long-term quality.

Low Leverage

A debt-to-equity ratio of about 0.15 gives the company meaningful financial flexibility and limits balance-sheet pressure. Modest leverage can help preserve capacity to fund pharmaceutical operations and absorb earnings volatility without making refinancing or interest obligations the primary risk.

Bears Say

Ongoing Losses

Net losses in both 2025 and the TTM period show that recent revenue momentum has not translated into dependable profitability. Negative operating profit weakens earnings quality, limits internally funded expansion from earnings, and leaves the company reliant on a future improvement in operations.

Margin Compression

The material decline in gross margin from the 2022–2023 peak suggests that the company is retaining less profit from each unit of revenue than previously. Continued pressure would reduce operating leverage and make the revenue rebound less valuable unless pricing, product mix, or costs improve.

Cash-flow Volatility

Although free cash flow remains positive and substantial, its roughly 14% year-over-year decline highlights uncertain cash-generation momentum. If this weakening trend persists, it could reduce self-funding capacity and make the recent cash-flow strength less dependable for investment and financial resilience.

8329 FAQ

What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.09 and its highest was HK$0.18 in the past 12 months.
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$233.24M.
When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H released its earnings results on Aug 25, 2026. The company reported HK$0.005 earnings per share for the quarter.
Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a dividend of HK$0.047 which represents an annual dividend yield of 3.86%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.
What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H reported an EPS of HK$0.005 in its last earnings report. Following the earnings report the stock price went up 1.835%.
Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8329
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology